SEC Form 4 · accession 0000899243-18-025421
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy L Ronneberg
Director
Period of report
Sep 25, 2018
Accepted (ET)
Sep 27, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001690585
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.67 | Sep 25, 2018 | A | 52,244 | A | — | Sep 24, 2028 | Common Stock | 52,244 | 52,244 | D |
Explanation of responses
- F1This option shall vest and become exercisable in 16 equal quarterly installments beginning on March 6, 2018.